Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
<i>In-vivo</i> antitrypanosomal effect and <i>in-silico</i> prediction of chronic toxicity of N-methylholaphyllamine in rats
Abstract
Purpose: To determine the in-vivo anti-trypanosomal effect and sub-chronic toxicity of Nmethylholaphyllamine (MHA) isolated from H. africana against Trypanosoma brucei in rats and also to predict its toxicity by an in-silico method.
Methods: Parasitemia was induced in rats with 1.5 x 105/mL trypanosomes and treatment commenced 5 days post-infection for 12 days. The rats were treated with MHA (3.5 μM/rat) for 5 days and with diminazene (3.5 mg/kg) for 2 days and were monitored every other day during and after treatment for the level of parasitemia and PCV. The chronic toxicity study was carried out with a 28-day sub-chronic toxicity cycle protocol while the toxicity was predicted in-silico with ProTox-II which is freely available on a web server.
Results: MHA exhibited anti-trypanosomal effect in infected rats leading to the restoration of PCV to baseline values (≥ 40 %) on the 14th day and consequent disappearance of parasitemia on day 17 post-infection with no relapse. The slight changes in clinical observation, weight, feed consumption, clinical and histopathology of high-dose MHA rats were not significant (p < 0.05) and were not attributed to the treatment. Apart from MHA-induced immunotoxicity observed in in-silico prediction, no other predicted toxicities were significant; however, few undetected toxicities were found to be mediated by amine oxidase A, androgen and/or histamine, H1 receptors toxicophore fit.
Conclusion: The high in-vivo antitrypanosomal effect and non-toxicity of MHA in this study further provide useful empirical data for lead optimization of MHA to combat sleeping sickness.
